Isamu Okamoto
Overview
Explore the profile of Isamu Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
367
Citations
12332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hakozaki T, Tanaka K, Shiraishi Y, Sekino Y, Mitome N, Okuma Y, et al.
J Thorac Oncol
. 2025 Mar;
PMID: 40058642
Background: Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker, but its role...
2.
Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, et al.
Lung Cancer
. 2025 Feb;
200:108102.
PMID: 39924255
Introduction: Data on chemotherapy for elderly, poor performance status (PS) non-small cell lung cancer (NSCLC) are clinically important but insufficient due to their exclusion from most interventional studies. This study...
3.
Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, et al.
Cancer Sci
. 2025 Feb;
PMID: 39904499
Anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) shows marked tumor shrinkage by ALK-tyrosine kinase inhibitors (TKIs). However, tumors almost inevitably relapse owing to the development of acquired...
4.
Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K, et al.
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860323
Lung malignancies, including cancerous lymphangitis and lymphomas, can mimic interstitial lung diseases like cryptogenic organizing pneumonia (COP) on imaging, leading to diagnostic delays. We aimed to identify potential biomarkers to...
5.
Ishii Y, Shiota A, Takao T, Yamamoto N, Ogawa T, Jo A, et al.
Allergol Int
. 2025 Jan;
PMID: 39809629
No abstract available.
6.
Takao T, Matsui A, Kikutake C, Kan-O K, Inoue A, Suyama M, et al.
Nat Commun
. 2025 Jan;
16(1):631.
PMID: 39805834
The root of asthma can be linked to early life, with prenatal environments influencing risk. We investigate the effects of maternal asthma on the offspring's lungs during fetal and adult...
7.
Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, et al.
Cancer Res
. 2025 Jan;
85(6):1082-1096.
PMID: 39804971
Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti-PD-1 mAb or anti-CTLA4 mAb seems to be less effective...
8.
Matsukane R, Nakamura S, Minami H, Tsubouchi K, Yoneshima Y, Hata K, et al.
J Immunother Cancer
. 2025 Jan;
12(12.
PMID: 39794938
Background: The immune-related adverse event (irAE), pneumonitis, is a potentially fatal complication of immune checkpoint inhibitors (ICIs). Preventing its progression is crucial, emphasizing the need for effective screening tests. We...
9.
Tsutsumi C, Ohuchida K, Tsutsumi H, Shimada Y, Yamada Y, Son K, et al.
Cancer Lett
. 2024 Dec;
611:217412.
PMID: 39722406
Therapies targeting HER2 are the standard treatment for HER2-positive gastric cancer (GC). Trastuzumab, a monoclonal antibody against HER2, exerts anti-tumor activity through cell growth regulation and antibody-dependent cellular cytotoxicity (ADCC)....
10.
Takano T, Tsubouchi K, Hamada N, Ichiki K, Torii R, Takata S, et al.
BMC Pulm Med
. 2024 Nov;
24(1):556.
PMID: 39506773
Background: We conducted a prospective observational study to elucidate the long-term prognosis and management of chronic obstructive pulmonary disease (COPD) in clinical practice in Japan in the mid-2010s. Methods: This...